Appen Limited (APPEF)
OTCMKTS · Delayed Price · Currency is USD
0.7471
0.00 (0.00%)
Aug 3, 2025, 8:00 PM EDT
Ligand Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 234.29 | 273.01 | 388.13 | 447.15 | 412.64 | Upgrade |
Other Revenue | 0.94 | 0.78 | 0.18 | 0.11 | 0.11 | Upgrade |
| 235.22 | 273.79 | 388.31 | 447.26 | 412.74 | Upgrade | |
Revenue Growth (YoY) | -14.09% | -29.49% | -13.18% | 8.36% | 9.71% | Upgrade |
Cost of Revenue | 197.36 | 251.62 | 331.93 | 339.39 | 317.85 | Upgrade |
Gross Profit | 37.86 | 22.17 | 56.38 | 107.87 | 94.9 | Upgrade |
Selling, General & Admin | 22.51 | 28.56 | 31.95 | 19.59 | 9.77 | Upgrade |
Other Operating Expenses | 8.69 | 9.84 | 9.72 | 8.67 | 14.39 | Upgrade |
Operating Expenses | 57.71 | 77.73 | 84.69 | 64.07 | 52.04 | Upgrade |
Operating Income | -19.85 | -55.56 | -28.31 | 43.8 | 42.86 | Upgrade |
Interest Expense | -0.82 | -1.53 | -1.77 | -2.03 | -2.5 | Upgrade |
Interest & Investment Income | 0.48 | 0.37 | 0.18 | 0.01 | 0.21 | Upgrade |
Currency Exchange Gain (Loss) | 4.35 | -4.03 | -2.56 | -1.18 | 4.66 | Upgrade |
Other Non Operating Income (Expenses) | -0.23 | -0.54 | - | - | - | Upgrade |
EBT Excluding Unusual Items | -16.07 | -61.29 | -32.46 | 40.6 | 45.23 | Upgrade |
Merger & Restructuring Charges | -3.92 | -10.47 | -2.28 | -4.73 | -3.25 | Upgrade |
Impairment of Goodwill | - | -53.11 | -188.94 | - | - | Upgrade |
Asset Writedown | - | -16.07 | -15.39 | - | - | Upgrade |
Other Unusual Items | - | 15.99 | - | - | 2.56 | Upgrade |
Pretax Income | -19.99 | -124.95 | -239.07 | 35.88 | 44.54 | Upgrade |
Income Tax Expense | 0.02 | -6.87 | - | 7.36 | 8.91 | Upgrade |
Net Income | -20.01 | -118.08 | -239.07 | 28.52 | 35.63 | Upgrade |
Net Income to Common | -20.01 | -118.08 | -239.07 | 28.52 | 35.63 | Upgrade |
Net Income Growth | - | - | - | -19.96% | 21.89% | Upgrade |
Shares Outstanding (Basic) | 229 | 142 | 123 | 123 | 122 | Upgrade |
Shares Outstanding (Diluted) | 229 | 142 | 123 | 125 | 124 | Upgrade |
Shares Change (YoY) | 61.11% | 15.17% | -1.16% | 0.94% | 2.82% | Upgrade |
EPS (Basic) | -0.09 | -0.83 | -1.94 | 0.23 | 0.29 | Upgrade |
EPS (Diluted) | -0.09 | -0.83 | -1.94 | 0.23 | 0.29 | Upgrade |
EPS Growth | - | - | - | -20.69% | 18.52% | Upgrade |
Free Cash Flow | -2.45 | -24.75 | 15.19 | 52.62 | 62.85 | Upgrade |
Free Cash Flow Per Share | -0.01 | -0.17 | 0.12 | 0.42 | 0.51 | Upgrade |
Dividend Per Share | - | - | - | 0.073 | 0.077 | Upgrade |
Dividend Growth | - | - | - | -5.75% | 22.02% | Upgrade |
Gross Margin | 16.10% | 8.10% | 14.52% | 24.12% | 22.99% | Upgrade |
Operating Margin | -8.44% | -20.29% | -7.29% | 9.79% | 10.38% | Upgrade |
Profit Margin | -8.51% | -43.13% | -61.57% | 6.38% | 8.63% | Upgrade |
Free Cash Flow Margin | -1.04% | -9.04% | 3.91% | 11.77% | 15.23% | Upgrade |
EBITDA | 1.51 | -24.88 | 8.01 | 73.6 | 66.08 | Upgrade |
EBITDA Margin | 0.64% | -9.09% | 2.06% | 16.46% | 16.01% | Upgrade |
D&A For EBITDA | 21.36 | 30.68 | 36.33 | 29.81 | 23.23 | Upgrade |
EBIT | -19.85 | -55.56 | -28.31 | 43.8 | 42.86 | Upgrade |
EBIT Margin | -8.44% | -20.29% | -7.29% | 9.79% | 10.38% | Upgrade |
Effective Tax Rate | - | - | - | 20.51% | 20.00% | Upgrade |
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.